348 Studies Now Enrolling
Menu
Search
Medical Condition
Displaying 1 - 7 of 7
Condition: COVID-19 (Coronavirus)
Investigator: Elizabeth Oelsner, MD, MPH
Status: Currently Recruiting
This study is called the COVID-19 Lung Microvascular and Parenchymal Sequelae (LUNG MaPS) Study. The purpose of the study is to learn about the effects of COVID-19 infections on the lungs and heart, and to improve our understanding of why some COVID-19 patients…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Usha Krishnan, MD
Status: Currently Recruiting
This study is being done to determine whether early combination therapy with two study drugs called sildenafil (REVATIO) and bosentan (TRACLEER) can improve pulmonary hypertension when compared to using sildenafil alone. Pediatric pulmonary arterial hypertension (PAH) is a severe medical problem that often worsens with time. It is caused by problems with…
Condition: COVID-19 (Coronavirus)
Investigator: Elisa Konofagou, PhD
Status: Closed
An ultrasound imaging study to assess the long terms effect of past COVID-19 infection in the heart, lung and vessels of recovered patients.
Condition: COVID-19 (Coronavirus)
Investigator: Christine Kim Garcia, MD
Status: Closed
Have you recovered from COVID-19 pneumonia? The FAR-ILD study is designed to detect and study the earliest stages of ILD in at-risk adults, including those who have had a severe viral pneumonia. FAR-ILD is a non-interventional study. This means that FAR-ILD is not involved in testing any new interventions or therapies. The purpose of FAR-ILD is to gather…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Erika Berman-Rosenzweig, MD
Status: Closed
This is a clinical research study designed to determine the safety and effectiveness of the TIVUS system, an investigational device used in the treatment of PAH. The TIVUS System is intended to treat patients with pulmonary artery hypertension by injuring the sympathetic nerves surrounding the pulmonary vasculature (denervation) using ultrasonic energy. The…
Condition: Lung Disease / Pulmonary Hypertension
Investigator: Elana Bernstein, MD
Status: Closed
This study involves two infusions of either rituximab or placebo, two right heart catheterizations (6 months apart), and a variety of other clinical study procedures and exams.
Condition: Lung Disease / Pulmonary Hypertension
Investigator: David Lederer, MD
Status: Closed
The purpose of this study is to study the effects of a new study drug known as Riociguat in people diagnosed with pulmonary hypertension (PH) associated with idiopathic interstitial pneumonia (IIP). Patients will be in the study for approximately 26 weeks in which they will take the pill Riogciguat three times a day.
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE